Ipamorelin is a synthetic five-residue peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classed among the growth hormone releasing peptides, and the published record describes it as a growth hormone secretagogue that binds the same pituitary receptor as the natural hormone ghrelin. What the literature returns to as its defining trait is selectivity: in preclinical work it raised growth hormone with little measurable effect on cortisol, prolactin, or ACTH. It is not FDA-approved for human therapeutic use, and the evidence base sits at the preclinical and early-investigational level rather than at finalized human clinical approval.
Ipamorelin is a synthetic pentapeptide secretagogue that prompts the pituitary to release its own growth hormone in a natural-pattern pulse, and it has not received marketing approval for human therapeutic use.
The structure is what gives ipamorelin its stability, and the record is specific about why. The molecule carries the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, the formula C38H49N9O5, and a free-base molecular weight near 711.9 daltons. Two of its residues fall outside the standard proteinogenic set, which is the structural reason it resists the enzymes that would otherwise break a natural peptide apart.
Ipamorelin is a five-residue peptide (C38H49N9O5, roughly 711.9 daltons) whose non-coded Aib cap, two D-amino acids, and amidated terminus make it markedly more resistant to proteolytic breakdown than a natural L-residue peptide of the same length.
The published mechanism traces a single signaling cascade from receptor to secretory pulse. Ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, a G-protein-coupled receptor expressed densely on pituitary somatotrophs and in parts of the hypothalamus. This is the same receptor and broadly the same pathway that endogenous ghrelin uses, so the peptide effectively mimics the natural ligand, though without ghrelin's appetite-stimulating activity to the same degree.
Ipamorelin activates the Gq/11 cascade at the GHS-R1a receptor, and the resulting calcium rise drives a discrete growth hormone pulse that can be amplified when growth hormone releasing hormone arrives at the pituitary at the same time.
The word "selective" in the literature points to a measured observation, not a marketing label: ipamorelin raised circulating growth hormone while producing little to no measurable change in other pituitary and adrenal hormones. In the foundational preclinical characterization it matched GHRP-6 for growth hormone potency but, unlike GHRP-6 and hexarelin, did not meaningfully elevate ACTH, cortisol, or prolactin even at doses well above what the growth hormone response required. That clean signal is the property most often cited to separate it from its predecessors.
Selectivity, for ipamorelin, means it raised growth hormone with potency comparable to GHRP-6 while leaving ACTH, cortisol, and prolactin essentially unchanged, even at doses above those needed to maximize the growth hormone response.
The most useful contrasts in the record run along two axes: scope of activity and side-effect profile. Ghrelin is a 28-amino-acid hormone with wide physiological reach, including strong appetite stimulation and gastric motility effects, while ipamorelin is a far smaller engineered molecule built to capture mainly the growth hormone releasing function. Against the earlier GHRPs the distinction is the hormonal noise, and against the releasing hormone analogs it is the receptor itself.
| Compound | Receptor / class | Key distinction from ipamorelin |
|---|---|---|
| Ghrelin | GHS-R1a, endogenous 28-aa hormone | Wide physiological roles including appetite and gastric motility |
| GHRP-6 / hexarelin | GHS-R1a secretagogues | Reliably raise cortisol and prolactin alongside growth hormone |
| CJC-1295 / sermorelin | GHRH receptor (distinct) | Act on a different receptor; can pair with a secretagogue for an additive pulse |
Ipamorelin shares the ghrelin receptor with GHRP-6 and hexarelin but was engineered to drop their cortisol and prolactin surge, and it targets a different receptor entirely from the GHRH analogs CJC-1295 and sermorelin, which is why a secretagogue and a releasing-hormone analog can produce a synergistic pulse together.
The downstream chain in the literature runs from a pituitary pulse to a liver-borne effector. Once growth hormone enters the circulation, a large share of its effect is carried by the liver's synthesis of insulin-like growth factor 1, the principal anabolic messenger that signals muscle, bone, and connective tissue. What the record emphasizes is the timing: the natural axis works in episodic bursts, and a pulsatile signal lets the somatostatin brake and receptor sensitivity reset between pulses, which is why secretagogue-driven release is often described as more physiological than a sustained elevation from injected recombinant growth hormone.
The growth hormone pulse ipamorelin triggers rises within minutes and resolves over one to two hours, with much of its downstream effect carried by liver-synthesized IGF-1 acting on muscle, bone, and connective tissue.
The feedback loop is central because ipamorelin supplies no growth hormone from outside the body; it prompts the pituitary to release its own, which keeps the release inside the body's own regulatory circuitry. Two restraining signals govern the size of the response, and together they mean the axis cannot be driven without limit. The published contrast is with injected recombinant growth hormone, where the dose bypasses the pituitary and blood levels are set by the injection rather than by the body's governors.
Because ipamorelin works through the pituitary's own stored growth hormone under the restraint of somatostatin and IGF-1 feedback, the literature characterizes its release as self-limiting, in contrast to injected recombinant growth hormone, which bypasses those governors and reaches sustained supraphysiologic levels more easily.
The pharmacokinetics reported in the record line up with a single, discrete pulse rather than a prolonged elevation. The plasma half-life is on the order of roughly two hours, and because peptides are not reliably absorbed by mouth, research and study settings administer ipamorelin by injection, most often subcutaneously. Its non-natural residues and amidated terminus give it more metabolic stability than an unmodified peptide of the same length, though it remains subject to proteolytic degradation and renal clearance.
Ipamorelin has a reported plasma half-life of roughly two hours and is administered by subcutaneous injection in research settings, and because it lacks human therapeutic approval, its pharmacokinetic profile rests on preclinical and early investigational data rather than a finalized clinical label.
Educational use only. This article describes what the published scientific and clinical literature reports about Ipamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
